EMEA-001164-PIP01-11-M08 - paediatric investigation plan
vonicog alfa
PIPHuman
Key facts
- Invented name
- Veyvondi
- Active Substance
- vonicog alfa
- Therapeutic area
- Congenital, familial and genetic disorders
- Decision number
- P/0236/2024
- PIP number
- EMEA-001164-PIP01-11-M08
- Pharmaceutical form(s)
- Powder and solvent for solution for injection
- Condition(s) / indication(s)
- Treatment of von Willebrand disease
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Baxalta Innovations GmbH
E-mail: medinfoEMEA@takeda.com
Tel. +44 (0)3333 000181- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date